Volunteerism and giving back to communities where we live and work are more than just tradition; they’re core values.

Novartis is one of 73 companies included in the 2017 Water A List by CDP, the nonprofit global environmental disclosure platform.

The third Novartis Social Business stakeholder dialogue took place on November 21 in Basel.

Novartis is committed to transforming the lives of people living with blood cancers and serious blood disorders.

Novartis is committed to reimagining the fight against Chagas Disease and advocating for an integrated, end-to-end care approach.

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.

Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with life-threatening blood cancers.
Novartis global commercial CAR-T manufacturing footprint now spans four continents, bringing these transformative therapies closer to patients and healthcare professionals around the world.

From January 21-24 2020, Novartis attended the World Economic Forum Annual Meeting in Davos, Switzerland.